Susquehanna International Group
MCRB icon

Susquehanna International Group’s Seres Therapeutics MCRB Stock Holding History

Susquehanna International Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$503K Sell
56,700
-12,000
-17% -$141K ﹤0.01% 9653
2025
Q4 		$1.02M Sell
68,700
-247,600
-78% -$4.32M ﹤0.01% 7144
2025
Q3 		$6.09M Buy
316,300
+233,100
+280% +$3.72M ﹤0.01% 3779
2025
Q2 		$924K Buy
83,200
+79,260
+2,012% +$697K ﹤0.01% 7633
2025
Q1 		$55.2K Sell
3,940
-129,750
-97% -$2.03M ﹤0.01% 11824
2024
Q4 		$2.22M Buy
133,690
+129,830
+3,363% +$2.11M ﹤0.01% 5070
2024
Q3 		$73.3K Buy
+3,860
New +$78.3K ﹤0.01% 11210
2024
Q1 		– Sell
-1,325
Closed -$37.1K – 12857
2023
Q4 		$37.1K Sell
1,325
-9,320
-88% -$245K ﹤0.01% 11819
2023
Q3 		$507K Sell
10,645
-1,935
-15% -$148K ﹤0.01% 8190
2023
Q2 		$1.21M Buy
12,580
+10,340
+462% +$1.13M ﹤0.01% 6255
2023
Q1 		$254K Buy
2,240
+1,005
+81% +$109K ﹤0.01% 10084
2022
Q4 		$138K Sell
1,235
-3,295
-73% -$442K ﹤0.01% 10604
2022
Q3 		$582K Buy
4,530
+2,320
+105% +$238K ﹤0.01% 8078
2022
Q2 		$152K Sell
2,210
-2,290
-51% -$197K ﹤0.01% 11004
2022
Q1 		$641K Sell
4,500
-855
-16% -$132K ﹤0.01% 8288
2021
Q4 		$892K Sell
5,355
-2,995
-36% -$476K ﹤0.01% 7589
2021
Q3 		$1.16M Buy
8,350
+1,655
+25% +$324K ﹤0.01% 7175
2021
Q2 		$3.19M Buy
6,695
+255
+4% +$108K ﹤0.01% 4884
2021
Q1 		$2.65M Sell
6,440
-2,580
-29% -$1.19M ﹤0.01% 5240
2020
Q4 		$4.42M Sell
9,020
-9,405
-51% -$5.51M ﹤0.01% 3622
2020
Q3 		$10.4M Buy
18,425
+13,430
+269% +$4.47M ﹤0.01% 2121
2020
Q2 		$476K Buy
+4,995
New +$438K ﹤0.01% 7464
2019
Q4 		– Sell
-7,200
Closed -$577K – 10259
2019
Q3 		$577K Sell
7,200
-9,270
-56% -$613K ﹤0.01% 6967
2019
Q2 		$1.06M Buy
16,470
+15,725
+2,111% +$1.49M ﹤0.01% 5507
2019
Q1 		$102K Buy
+745
New +$90.8K ﹤0.01% 8240
2018
Q4 		– Sell
-1,040
Closed -$158K – 9542
2018
Q3 		$158K Sell
1,040
-1,275
-55% -$206K ﹤0.01% 8387
2018
Q2 		$398K Sell
2,315
-2,360
-50% -$386K ﹤0.01% 7264
2018
Q1 		$686K Buy
4,675
+330
+8% +$63.3K ﹤0.01% 6001
2017
Q4 		$881K Buy
4,345
+3,430
+375% +$705K ﹤0.01% 5488
2017
Q3 		$294K Sell
915
-2,570
-74% -$702K ﹤0.01% 7432
2017
Q2 		$788K Buy
3,485
+1,250
+56% +$257K ﹤0.01% 5764
2017
Q1 		$504K Buy
2,235
+1,215
+119% +$247K ﹤0.01% 6476
2016
Q4 		$202K Sell
1,020
-850
-45% -$185K ﹤0.01% 8638
2016
Q3 		$460K Sell
1,870
-10
-0.5% -$3.51K ﹤0.01% 6212
2016
Q2 		$1.09M Buy
+1,880
New +$1.1M ﹤0.01% 4706
2016
Q1 		– Sell
-3,520
Closed -$2.47M – 9405
2015
Q4 		$2.47M Buy
3,520
+2,975
+546% +$1.96M ﹤0.01% 3631
2015
Q3 		$323K Buy
+545
New +$445K ﹤0.01% 7909

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group's MCRB Position: Q1 2026 in Review

Susquehanna International Group reduced its Seres Therapeutics (MCRB) stake by 41% in Q1 2026, selling an estimated $874K and leaving 105,339 shares worth $934K. The position accounts for ﹤0.01% of the portfolio, ranked #8048.

Susquehanna International Group first reported a position in MCRB in Q3 2015 and has held it in 31 quarters since. The position peaked at $5.29M in Q4 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Susquehanna International Group held 105,339 shares of Seres Therapeutics worth $934K as of Q1 2026.
  • Susquehanna International Group sold 74,590 Seres Therapeutics shares in Q1 2026, an estimated $874K.
  • Seres Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8048 holding.
  • Susquehanna International Group first reported a position in Seres Therapeutics in Q3 2015 and has held it in 31 quarters since.
  • Susquehanna International Group's Seres Therapeutics position peaked at $5.29M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.